IUPAC/Chemical Name
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-isopropyl-N-(isopropylcarbamoyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
InChi Key
WMPQMBUXZHMEFZ-YJPJVVPASA-N
InChi Code
InChI=1S/C27H45N3O3/c1-16(2)28-25(33)30(17(3)4)24(32)21-10-9-19-18-8-11-22-27(6,15-13-23(31)29(22)7)20(18)12-14-26(19,21)5/h16-22H,8-15H2,1-7H3,(H,28,33)/t18-,19-,20-,21+,22+,26-,27+/m0/s1
SMILES Code
CC(NC(N(C([C@H]1CC[C@H]2[C@@H]3CC[C@H]4N(C(CC[C@@]4([C@H]3CC[C@]12C)C)=O)C)=O)C(C)C)=O)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
459.68
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995 Sep;54(5-6):273-9. doi: 10.1016/0960-0760(95)00134-l. PMID: 7577710.
2: Zaccheo T, Giudici D, di Salle E. Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate. 1997 Feb 1;30(2):85-91. doi: 10.1002/(sici)1097-0045(19970201)30:2<85::aid- pros3>3.0.co;2-j. PMID: 9051146.
3: Persiani S, Broutin F, Pianezzola E, Panzeri A, Fonte G, Fontana E, Strolin Benedetti M. Radioimmunoassay for the testosterone 5 alpha-reductase inhibitor turosteride in biological fluids. J Immunoassay. 1994 May;15(2):97-113. doi: 10.1080/15321819408013941. PMID: 8040353.
4: Di Salle E, Briatico G, Giudici D, Ornati G, Panzeri A. Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol. 1994 Feb;48(2-3):241-8. doi: 10.1016/0960-0760(94)90151-1. PMID: 8142301.
5: Zaccheo T, Giudici D, di Salle E. Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. Prostate. 1998 Jun 1;35(4):237-42. doi: 10.1002/(sici)1097-0045(19980601)35:4<237::aid-pros1>3.0.co;2-d. PMID: 9609545.
6: di Salle E, Giudici D, Briatico G, Ornati G, Panzeri A. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55. doi: 10.1016/0960-0760(93)90181-u. PMID: 8240976.
7: Basileo G, Casati M, Pianezzola E, Strolin Benedetti M. Determination of turosteride, a new inhibitor of 5 alpha-reductase, in human plasma by high- performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1997 Jan 10;688(1):117-25. doi: 10.1016/s0378-4347(97)88063-2. PMID: 9029321.
8: Seiffert K, Seltmann H, Fritsch M, Zouboulis CC. Inhibition of 5alpha- reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. Horm Metab Res. 2007 Feb;39(2):141-8. doi: 10.1055/s-2007-961814. PMID: 17326010.
